Abstract:Background: The robustness and reproducibility of transcriptomics-derived models were limited by the various microenvironmental conditions like stromal context and tumor purity. We aimed to explore a robust prognostic and immunotherapeutic predictive model by differentiating cell origins in lung adenocarcinoma (LUAD).Methods: A total of 2,451 patients in 12 independent cohorts with transcriptomic data, including 10 public datasets and two in-house cohorts, were analyzed. The tumor immune cell score (TICS) and tumor stromal score (TSCS) was developed depending on the candidate immune or stromal cells in the training meta-cohorts (n=6), and then verified in four datasets. Therapeutic responses including immune checkpoint inhibitors (ICIs), chemotherapy and tyrosine kinase inhibitor (TKI) were compared between high- and low- TICS groups in the advanced-stage LUAD.Finding: The TICS, instead of TSCS, contributed majorly for predicting clinical outcomes in LUAD. The high TICS was associated with a prolonged overall survival (OS) in the training meta-cohorts (HR 0·55, 95%CI 0·45-0·66) and was validated in three public cohorts and one in-house cohort. The prognostic efficacy of TICS was more significant in the early-stage LUAD (HR=0·49, 95%CI: 0·38-0·63). For the advanced-stage LUAD, high TICS predicted a superior OS in patients who treated with ICIs (HR 0·09, 95% CI 0·02-0·32) instead of chemotherapy (HR 0·84, 95% CI 0·30-2·30) or TKI (HR 1·20, 95% CI 0·08-20·00).Interpretation: TICS is associated with survival in patients with LUAD, and may serve as a predictor for the benefit of ICIs in advanced LUAD.Funding Information: National Natural Sciences Foundation (82102886 for JX); Beijing Nova Program (Z211100002121055 for ZY); the Special Research Fund for Central Universities, Peking Union Medical College (3332021029 for JX); National Natural Sciences Foundation (82203827 for ZY); the Special Research Fund for Central Universities, Peking Union Medical College (3332021028 for ZY); Beijing Natural Science Foundation (7222146 for ZY); Guangdong Association of Clinical Trials (GACT) /Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120); Beijing Hope Run Special Fund of Cancer Foundation of China (LC2021B22, LC2020B09, LC2020A33); the National Natural Sciences Foundation (81871889 and 82072586 for ZW) and Beijing Natural Science Foundation (7212084 for ZW).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: All patients have informed consent and this study was approved by the ethics committees of the National Cancer Center (NCC-22/250-3454, NCC-22/429-3631). Patients without follow-up information were removed from further evaluation.

A&nbsp;Novel Prognostic and Immunotherapeutic Predictive Model Based On&nbsp;cell-Originated Characterization of Tumor Microenvironment in Lung Adenocarcinoma

A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.

A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma

T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing

A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma

Dissection of the cell communication interactions in lung adenocarcinoma identified a prognostic model with immunotherapy efficacy assessment and a potential therapeutic candidate gene ITGB1

A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma.

A Single-Cell Characterised Signature Integrating Heterogeneity and Microenvironment of Lung Adenocarcinoma for Prognostic Stratification

Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma

Trans-omics Biomarker Model Improves Prognostic Prediction Accuracy for Early-Stage Lung Adenocarcinoma.

Transcriptional Characterization of the Tumor Immune Microenvironment and Its Prognostic Value for Locally Advanced Lung Adenocarcinoma in A Chinese Population

Identification of a novel oxidative stress-related prognostic model in lung adenocarcinoma

A Novel Prognostic Model of Early-Stage Lung Adenocarcinoma Integrating Methylation and Immune Biomarkers

A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma

Identification of prognostic molecular subtypes and model based on CD8+ T cells for lung adenocarcinoma

Machine-learning and scRNA-Seq-based diagnostic and prognostic models illustrating survival and therapy response of lung adenocarcinoma

Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma

Single-cell RNA sequencing analysis to explore immune cell heterogeneity and novel biomarkers for the prognosis of lung adenocarcinoma

A&amp;nbsp;Novel Prognostic and Immunotherapeutic Predictive Model Based On&amp;nbsp;cell-Originated Characterization of Tumor Microenvironment in Lung Adenocarcinoma